The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience-Reference-Cited by-同舟云学术

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Published:2012-12-13 Issue:25 Volume:120 Page:5084-5085
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lamarque Mathilde¹,Raynaud Sophie²,Itzykson Raphael¹,Thepot Sylvain³,Quesnel Bruno⁴,Dreyfus Francois⁵,Rauzy Odile Beyne⁶,Turlure Pascal⁷,Vey Norbert⁸,Recher Christian⁶,Dartigeas Caroline⁹,Legros Laurence²,Delaunay Jacques¹⁰,Visanica Sorin¹¹,Stamatoullas Aspasia¹²,Fenaux Pierre³,Adès Lionel³

Affiliation:

1. Groupe Francophone des Myelodysplasies, Bobigny, France

2. Groupe Francophone des Myelodysplasies, Bobigny, France and Université de Nice Sophia Antipolis, Faculté de Médecine, Nice, France

3. Groupe Francophone des Myelodysplasies, Bobigny, France and Hopital Avicenne, Université Paris 13 Paris, France

4. Groupe Francophone des Myelodysplasies, Bobigny, France and Service des Maladie du Sang, Centre Hospitalier Universitaire, Lille, France

5. Groupe Francophone des Myelodysplasies, Bobigny, France and Hopital Cochin, Universitaire Paris 5, Paris, France

6. Groupe Francophone des Myelodysplasies, Bobigny, France and Hopital Purpan, Centre Hospitalier Universitaire, Toulouse, France

7. Groupe Francophone des Myelodysplasies, Bobigny, France and Hopital Dupuytren, Centre Hospitalier Universitaire, Limoges, France

8. Groupe Francophone des Myelodysplasies, Bobigny, France and Institut Paoli Calmettes, Marseille, France

9. Groupe Francophone des Myelodysplasies, Bobigny, France and Centre Hospitalier Universitaire, Tours, France

10. Groupe Francophone des Myelodysplasies, Bobigny, France and Centre Hospitalier Universitaire, Nantes, France

11. Groupe Francophone des Myelodysplasies, Bobigny, France and Centre Hospitalier Metz, Metz, France

12. Groupe Francophone des Myelodysplasies, Bobigny, France and Centre Henri Becquerel, Rouen, France

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/120/25/5084/1358684/zh805112005084.pdf

Reference4 articles.

1. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes.;Greenberg;Blood,2012

2. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.;Schanz;J Clin Oncol,2011

3. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.;Itzykson;Blood,2011

4. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.;Cheson;Blood,2006

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis;Cancers;2024-03-29

2. Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes;International Journal of Molecular Sciences;2022-03-03

3. How low risk are low risk myelodysplastic syndromes?;Expert Review of Hematology;2022-01-02

4. Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis;Leukemia Research;2021-11

5. Comparison of Upfront Transplantation and Pretransplant Cytoreductive Therapy for Advanced Myelodysplastic Syndrome;Clinical Lymphoma Myeloma and Leukemia;2021-09